Lumos Pharma, Inc. (LUMO) Tops Q2 EPS by 24c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q2 EPS of ($0.93), $0.24 better than the analyst estimate of ($1.17). Revenue for the quarter came in at $490 thousand versus the consensus estimate of $265 thousand.

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Is Treasury selloff a major issue for stock market bulls?
• Stifel on EyePoint Inc. (EYPT): 'we think these data bode well for LUCIA (expected October) barring another unusual asymmetry'